 |
Ancestim |
|---|---|
| Trade Name | Stemgen |
| Orphan Indication | For use in combination with filgrastim to decrease the number of phereses required to collect peripheral blood progenitor cells capable of providing rapid multi-lineage hematopoietic reconstitution following myelosuppressive or myeloablative therapy |
| USA Market Approval | USA |
| USA Designation Date | 1995-07-05 00:00:00 |
| Sponsor | Amgen, Inc.;One Amgen Center Drive;Thousand Oaks, California, 91320 |
